Chardan Capital Comments on MeiraGTx FY2026 Earnings

MeiraGTx Holdings plc (NASDAQ:MGTX) – Equities research analysts at Chardan Capital issued their FY2026 earnings per share (EPS) estimates for shares of MeiraGTx in a research note issued on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will post earnings per share of ($1.09) for the year. Chardan Capital currently has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for MeiraGTx’s current full-year earnings is ($1.48) per share.

Separately, Royal Bank of Canada lifted their price objective on MeiraGTx from $11.00 to $13.00 and gave the company an “outperform” rating in a report on Monday, March 17th.

MeiraGTx Stock Up 2.2 %

Shares of NASDAQ:MGTX opened at $7.39 on Thursday. The company has a market cap of $582.74 million, a price-to-earnings ratio of -6.11, a PEG ratio of 0.37 and a beta of 1.23. MeiraGTx has a fifty-two week low of $3.85 and a fifty-two week high of $8.75. The firm’s 50-day simple moving average is $6.81 and its 200-day simple moving average is $6.03. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86.

MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). MeiraGTx had a negative net margin of 633.05% and a negative return on equity of 146.38%. The firm had revenue of $21.39 million during the quarter, compared to analyst estimates of $1.50 million.

Hedge Funds Weigh In On MeiraGTx

Hedge funds have recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. increased its position in MeiraGTx by 106.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,871 shares of the company’s stock worth $30,000 after purchasing an additional 2,515 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in MeiraGTx by 68.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,975 shares of the company’s stock worth $30,000 after acquiring an additional 2,016 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of MeiraGTx by 142.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company’s stock worth $39,000 after purchasing an additional 5,476 shares during the period. Polymer Capital Management US LLC acquired a new stake in shares of MeiraGTx during the fourth quarter worth $88,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of MeiraGTx by 11.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,571 shares of the company’s stock valued at $101,000 after purchasing an additional 1,685 shares during the period. 67.48% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other MeiraGTx news, CFO Richard Giroux sold 24,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total transaction of $150,960.00. Following the transaction, the chief financial officer now directly owns 849,947 shares in the company, valued at approximately $5,346,166.63. This represents a 2.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Alexandria Forbes sold 35,839 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $6.47, for a total transaction of $231,878.33. Following the completion of the transaction, the chief executive officer now directly owns 1,395,102 shares of the company’s stock, valued at approximately $9,026,309.94. This trade represents a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.40% of the stock is currently owned by company insiders.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.